MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-11-2026
Stryker Corporation Gross Profit 2011-2026 | SYK
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Stryker Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.63 B | 4.17 B | 13.1 B | 11.6 B | 11 B | 9.06 B | 9.7 B | 8.94 B | 8.17 B | 7.5 B | 6.6 B | 6.38 B | 6.04 B | 5.88 B | 5.5 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.1 B | 4.17 B | 7.88 B |
Quarterly Gross Profit Stryker Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.85 B | 3.84 B | 3.74 B | 3.52 B | 3.42 B | 3.33 B | 3.16 B | 3.18 B | 3.02 B | - | 2.78 B | 2.83 B | 2.73 B | 3.04 B | 2.64 B | 2.77 B | 2.51 B | 2.72 B | 2.46 B | 1.55 B | 2.33 B | 2.7 B | 2.33 B | 2.38 B | 2.28 B | 2.46 B | 2.16 B | 2.19 B | 2.14 B | 2.24 B | 1.98 B | 1.99 B | 1.96 B | 2.09 B | 1.87 B | 1.84 B | 1.69 B | 1.82 B | 1.62 B | 1.6 B | 1.55 B | 1.72 B | 1.56 B | 1.55 B | 1.53 B | 1.62 B | 1.47 B | 1.48 B | 1.48 B | 1.59 B | 1.4 B | 1.43 B | 1.45 B | 1.48 B | 1.36 B | 1.33 B | 1.33 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.85 B | 1.33 B | 2.22 B |
Gross Profit of other stocks in the Medical devices industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioSig Technologies
BSGM
|
229 K | - | 37.08 % | $ 85.7 M |  USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
67.9 M | - | - | $ 1.77 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
198 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
6.6 M | - | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
-3.14 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
443 K | - | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
584 K | - | -5.86 % | $ 30.6 M | USA |
 |
Penumbra
PEN
|
942 M | $ 335.76 | 0.45 % | $ 13.1 B | USA |
 |
Second Sight Medical Products
EYES
|
500 K | - | -0.97 % | $ 54.4 M | USA |
 |
Insulet Corporation
PODD
|
1.94 B | $ 221.53 | -1.76 % | $ 15.6 B | USA |
 |
Conformis
CFMS
|
23.2 M | - | - | $ 16.4 M | USA |
 |
Profound Medical Corp.
PROF
|
4.38 M | $ 5.73 | 11.26 % | $ 180 M |  Canada |
 |
Cardiovascular Systems
CSII
|
173 M | - | 0.15 % | $ 844 M | USA |
 |
Quanterix Corporation
QTRX
|
65 M | $ 4.0 | 4.71 % | $ 171 M | USA |
 |
Apollo Endosurgery
APEN
|
42.4 M | - | - | $ 475 M | USA |
 |
AVITA Medical
RCEL
|
58.8 M | $ 3.97 | 3.39 % | $ 111 M |  Australia |
 |
Avinger
AVGR
|
2 M | - | -20.74 % | $ 369 K | USA |
 |
CryoLife, Inc.
CRY
|
168 M | - | -4.14 % | $ 702 M | USA |
 |
CONMED Corporation
CNMD
|
750 M | $ 36.75 | 0.45 % | $ 1.14 B | USA |
 |
Sintx Technologies
SINT
|
461 K | $ 2.6 | 1.17 % | $ 7.21 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
28.7 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
NanoVibronix
NAOV
|
1.51 M | - | - | $ 1.08 M | USA |
 |
Electromed
ELMD
|
50 M | $ 24.89 | 0.77 % | $ 210 M | USA |
 |
Smith & Nephew plc
SNN
|
4.05 B | $ 32.38 | 0.67 % | $ 23.8 B |  Britain |
 |
Misonix, Inc.
MSON
|
43.7 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
1.99 M | - | - | $ 111 M | Canada |
 |
Sensus Healthcare
SRTS
|
11.9 M | $ 4.23 | 6.82 % | $ 69.1 M | USA |
 |
MiMedx Group
MDXG
|
346 M | $ 4.13 | - | $ 610 M | USA |
 |
Intersect ENT, Inc.
XENT
|
50.2 M | - | - | $ 955 M | USA |
 |
Cytosorbents Corporation
CTSO
|
25.1 M | $ 0.69 | -1.55 % | $ 37.6 M | USA |
 |
Aethlon Medical
AEMD
|
1.36 M | $ 2.29 | 5.9 % | $ 3.57 M | USA |
 |
Tactile Systems Technology
TCMD
|
250 M | $ 27.7 | 3.13 % | $ 634 M | USA |
 |
BIOLASE
BIOL
|
16.7 M | - | -13.19 % | $ 166 K | USA |
 |
TELA Bio
TELA
|
40.1 M | $ 0.7 | -8.05 % | $ 16 M | USA |
 |
Orthofix Medical
OFIX
|
566 M | $ 11.82 | 0.81 % | $ 468 M |  Curacao |
 |
InspireMD
NSPR
|
2.65 M | $ 1.78 | -0.84 % | $ 114 M | Israel |
 |
Tandem Diabetes Care
TNDM
|
167 M | $ 24.17 | -1.41 % | $ 1.64 B | USA |
 |
AdaptHealth Corp.
AHCO
|
89.3 M | $ 11.42 | -0.52 % | $ 1.54 B | USA |
 |
Myomo
MYO
|
26.9 M | $ 0.7 | -0.27 % | $ 29.3 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
-10.6 M | $ 2.33 | -3.13 % | $ 137 M | Israel |
 |
Invacare Corporation
IVC
|
48.3 M | - | - | $ 24.7 M | USA |
 |
EDAP TMS S.A.
EDAP
|
26.6 M | $ 3.7 | -5.37 % | $ 138 M |  France |
 |
OrthoPediatrics Corp.
KIDS
|
173 M | $ 16.3 | 2.45 % | $ 382 M | USA |
 |
Outset Medical
OM
|
46.8 M | $ 3.48 | -1.45 % | $ 52.9 K | USA |
 |
Inspire Medical Systems
INSP
|
779 M | $ 51.73 | -0.67 % | $ 1.52 B | USA |
 |
Pulmonx Corporation
LUNG
|
67.1 M | $ 1.3 | -1.15 % | $ 52.9 M | USA |